Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jonathan Feld, Abigail Belasen & Shyamala C Navada. (2020) Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years. Expert Review of Anticancer Therapy 20:6, pages 465-482.
Read now
Read now
Roberto Castelli, Luigi Bergamaschini, Riccardo Schiavon & Giorgio Lambertenghi-Deliliers. (2017) Personalized treatment strategies for elderly patients with myelodysplastic syndromes. Expert Review of Hematology 10:12, pages 1077-1086.
Read now
Read now
David J Seastone & Aaron T Gerds. (2015) Darbepoetin alfa for anemia with myelodysplastic syndrome. Expert Review of Hematology 8:2, pages 139-146.
Read now
Read now
Articles from other publishers (24)
Allison Mo, Matthew Poynton, Erica Wood, Jake Shortt, Susan J. Brunskill, Carolyn Doree, Josie Sandercock, Nicholas Saadah, Edwin Luk, Simon J. Stanworth & Zoe McQuilten. (2023) Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review. Blood Reviews 61, pages 101114.
Crossref
Crossref
Muzeyyen Aslaner Ak, Birsen Sahip, Ayfer Geduk, Mehmer Ali Ucar, Hacer Kale, Tugba Hacibekiroglu, Merve Gokcen Polat, Yasin Kalpakci, Ali Zahit Bolaman, Birol Guvenc & Sehmus Ertop. (2021) The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study. Indian Journal of Hematology and Blood Transfusion 38:2, pages 299-308.
Crossref
Crossref
Esther Natalie Oliva, Uwe Platzbecker, Guillermo Garcia-Manero, Ghulam J. Mufti, Valeria Santini, Mikkael A. Sekeres, Rami S. Komrokji, Jeevan K. Shetty, Derek Tang, Shien Guo, Weiqin Liao, George Zhang, Xianwei Ha, Rodrigo Ito, Jennifer Lord-Bessen, Jay T. Backstrom & Pierre Fenaux. (2021) Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial. Journal of Clinical Medicine 11:1, pages 27.
Crossref
Crossref
Esther N. Oliva, Uwe Platzbecker, Pierre Fenaux, Guillermo Garcia-Manero, Thomas W. LeBlanc, Bhumika J. Patel, Anne Sophie Kubasch & Mikkael A. Sekeres. (2021) Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned. Blood Reviews 50, pages 100851.
Crossref
Crossref
Karen-Sue B. Carlson, Joshua Morris, Lauryn P. Cross & Sridhar Rao. 2020. Contemporary Bone Marrow Transplantation. Contemporary Bone Marrow Transplantation
1
14
.
Karen-Sue B. Carlson, Joshua Morris, Lauryn P. Cross & Sridhar Rao. 2021. Contemporary Bone Marrow Transplantation. Contemporary Bone Marrow Transplantation
29
42
.
Sophie Park, Charikleia Kelaidi, Mathieu Meunier, Nicole Casadevall, Aaron T. Gerds & Uwe Platzbecker. (2019) The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. Annals of Hematology 99:1, pages 7-19.
Crossref
Crossref
Uma Borate, Brianna A. NorrisAbby Statler, Rongwei Fu, Taylor BucyMikkael A. Sekeres. (2019) Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years. Blood Advances 3:18, pages 2738-2747.
Crossref
Crossref
Pere Gascón, Andriy Krendyukov, Nicola Mathieson & Matti Aapro. (2019) Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols. Leukemia Research 81, pages 35-42.
Crossref
Crossref
Lucas Affentranger, Julia Bohlius, Mahmoud Hallal & Nicolas Bonadies. (2019) Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review. Critical Reviews in Oncology/Hematology 136, pages 37-47.
Crossref
Crossref
Sophie Park, Peter Greenberg, Aylin Yucel, Caroline Farmer, Frank O'Neill, Cisio De Oliveira Brandao & Pierre Fenaux. (2018) Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review. British Journal of Haematology 184:2, pages 134-160.
Crossref
Crossref
Roberto Castelli, Riccardo Schiavon & Giorgio Lambertenghi Deliliers. (2018) The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes. Medical Oncology 35:3.
Crossref
Crossref
S. Park & K. Götze. 2018. Myelodysplastic Syndromes. Myelodysplastic Syndromes
83
95
.
U Platzbecker, A Symeonidis, E N Oliva, J S Goede, M Delforge, J Mayer, B Slama, S Badre, E Gasal, B Mehta & J Franklin. (2017) A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia 31:9, pages 1944-1950.
Crossref
Crossref
Antonio Gidaro, Giorgio Lambertenghi Deliliers, Paolo Gallipoli, Massimo Arquati, Maddalena Alessandra Wu & Roberto Castelli. (2016) Laboratory and clinical risk assessment to treat myelodysplatic syndromes. Clinical Chemistry and Laboratory Medicine (CCLM) 54:9, pages 1411-1426.
Crossref
Crossref
Sophie Park, Pierre Fenaux, Peter Greenberg, Bhakti Mehta, Fiona Callaghan, Christopher Kim, Dianne Tomita & Hairong Xu. (2016) Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta‐analysis. British Journal of Haematology 174:5, pages 730-747.
Crossref
Crossref
Jun Ho Jang, Hironori Harada, Hirohiko Shibayama, Ryutaro Shimazaki, Hyeoung-Joon Kim, Kenichi Sawada & Kinuko Mitani. (2015) A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. International Journal of Hematology 102:4, pages 401-412.
Crossref
Crossref
Nataša Debeljak, Peter Solár & Arthur J. Sytkowski. (2014) Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction. Frontiers in Immunology 5.
Crossref
Crossref
Roberto Castelli, Giorgio Lambertenghi Deliliers, Riccardo Colombo, Guido Moreo, Paolo Gallipoli & Giuseppe Pantaleo. (2014) Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. Annals of Hematology 93:9, pages 1523-1529.
Crossref
Crossref
Luca MalcovatiEva Hellström-LindbergDavid BowenLionel AdèsJaroslav CermakConsuelo del CañizoMatteo G. Della Porta, Pierre FenauxNorbert GattermannUlrich GermingJoop H. JansenMoshe MittelmanGhulam MuftiUwe PlatzbeckerGuillermo F. SanzDominik SelleslagMette Skov-HolmReinhard StauderArgiris Symeonidis, Arjan A. van de Loosdrecht, Theo de WitteMario Cazzola. (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122:17, pages 2943-2964.
Crossref
Crossref
C. Kelaidi, O. Beyne-Rauzy, T. Braun, R. Sapena, P. Cougoul, L. Adès, F. Pillard, C. Lambert, J. C. Charniot, A. Guerci, B. Choufi, A. Stamatoullas, B. Slama, B. De Renzis, S. Ame, G. Damaj, F. Boyer, M. P. Chaury, L. Legros, S. Cheze, A. Testu, E. Gyan, M. C. Béné, C. Rose, F. Dreyfus & P. Fenaux. (2013) High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Annals of Hematology 92:5, pages 621-631.
Crossref
Crossref
Valeria Santini. (2012) Treatment of Low-Risk Myelodysplastic Syndrome: Hematopoietic Growth Factors Erythropoietins and Thrombopoietins. Seminars in Hematology 49:4, pages 295-303.
Crossref
Crossref
Elena Crisà, Cristina Foli, Roberto Passera, Antonella Darbesio, Kimberly B. Garvey, Mario Boccadoro & Dario Ferrero. (2012)
Long‐term follow‐up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13‐
cis
‐retinoic acid and dihydroxylated vitamin
D
3: independent positive impact of erythroid response on survival
. British Journal of Haematology 158:1, pages 99-107.
Crossref
Crossref
Mary Laudon Thomas, Nicole Crisp & Karen Campbell. (2012) The Importance of Quality of Life for Patients Living With Myelodysplastic Syndromes. Clinical Journal of Oncology Nursing 16:0, pages 47-57.
Crossref
Crossref